» Articles » PMID: 25692019

Functional Desensitization of the β 2 Adrenoceptor is Not Dependent on Agonist Efficacy

Overview
Date 2015 Feb 19
PMID 25692019
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic treatment with β 2 adrenoceptor agonists is recommended as a first-line maintenance therapy for chronic obstructive pulmonary disease (COPD). However, a potential consequence of long-term treatment may be the loss of functional response (tachyphylaxis) over time. In this study, we have investigated the tendency of such agonists, with a range of efficacies, to develop functional desensitization to cAMP responses in primary human bronchial smooth muscle cells following prolonged agonist exposure. The data show that upon repeat exposure, all agonists produced functional desensitization to the same degree and rate. In addition, β 2 adrenoceptor internalization and β-arrestin-2 recruitment were monitored using β 2·eGFP visualization and the PathHunter™ β-arrestin-2 assay, respectively. All agonists were capable of causing robust receptor internalization and β-arrestin-2 recruitment, the rate of which was influenced by agonist efficacy, as measured in those assays. In summary, although a relationship exists between agonist efficacy and the rate of both receptor internalization and β-arrestin-2 recruitment, there is no correlation between agonist efficacy and the rate or extent of functional desensitization.

Citing Articles

ROS-mediated regulation of β2AR function: Does oxidation play a meaningful role towards β2-agonist tachyphylaxis in airway obstructive diseases?.

Teyani R, Moghaddam F, Moniri N Biochem Pharmacol. 2024; 226:116403.

PMID: 38945277 PMC: 11301793. DOI: 10.1016/j.bcp.2024.116403.


Beta-blockers reduce severe exacerbation in patients with mild chronic obstructive pulmonary disease with atrial fibrillation: a population-based cohort study.

Lin S, Liao X, Chen N, Chang Y, Cheng C BMJ Open Respir Res. 2023; 10(1).

PMID: 37989489 PMC: 10660430. DOI: 10.1136/bmjresp-2023-001854.


"As-Needed" Inhaled Corticosteroids for Patients With Asthma.

Cardet J, Papi A, Reddel H J Allergy Clin Immunol Pract. 2023; 11(3):726-734.

PMID: 36702246 PMC: 10006338. DOI: 10.1016/j.jaip.2023.01.010.


The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response.

Roberts M, Broome R, Kent T, Charlton S, Rosethorne E Respir Res. 2018; 19(1):56.

PMID: 29625570 PMC: 5889558. DOI: 10.1186/s12931-018-0759-2.

References
1.
McGraw D, Liggett S . Heterogeneity in beta-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the beta2-adrenergic receptor. J Biol Chem. 1997; 272(11):7338-44. DOI: 10.1074/jbc.272.11.7338. View

2.
Fitzgerald J, Chapman K, Della Cioppa G, Stubbing D, Fairbarn M, Till M . Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immunol. 1999; 103(3 Pt 1):427-35. DOI: 10.1016/s0091-6749(99)70467-7. View

3.
Donohue J, Menjoge S, Kesten S . Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med. 2003; 97(9):1014-20. DOI: 10.1016/s0954-6111(03)00131-8. View

4.
Clark R, Knoll B, Barber R . Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci. 1999; 20(7):279-86. DOI: 10.1016/s0165-6147(99)01351-6. View

5.
Charlton S . Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol. 2009; 158(1):165-8. PMC: 2795257. DOI: 10.1111/j.1476-5381.2009.00352.x. View